Literature DB >> 24839370

Chronic Neutrophilic Leukemia with V617F JAK2 Mutation.

Smeeta Gajendra1, Ritu Gupta1, Meenal Chandgothia1, Lalit Kumar2, Richa Gupta1, Snehal Motilal Chavan3.   

Abstract

Chronic neutrophilic leukemia (CNL) is a rare disease grouped under World health organization classification as chronic myeloproliferative disease. It is a diagnosis of exclusion in patients with sustained mature neutrophilia and splenomegaly with no evidence of other myeloproliferative disease or reactive neutrophilia. V617F JAK 2 mutation has been described in classical myeloproliferative diseases, but its association with CNL has been reported in a few cases. Here in, we describe three cases of CNL with presence of V617F JAK 2 mutation. To distinguish CNL from secondary neutrophilia can be difficult. Detection of the V617F JAK 2 mutation in such scenario can provide a useful diagnostic test to establish the neoplastic nature of the neutrophilia.

Entities:  

Keywords:  Chronic myeloproliferative disease; Chronic neutrophilic leukemia; V617F JAK 2 mutation

Year:  2012        PMID: 24839370      PMCID: PMC4022913          DOI: 10.1007/s12288-012-0203-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  12 in total

Review 1.  Chronic neutrophilic leukaemia: a distinct clinical entity?

Authors:  John T Reilly
Journal:  Br J Haematol       Date:  2002-01       Impact factor: 6.998

2.  WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature.

Authors:  M A Elliott; C A Hanson; G W Dewald; S A Smoley; T L Lasho; A Tefferi
Journal:  Leukemia       Date:  2005-02       Impact factor: 11.528

3.  Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.

Authors:  Donald P Mc Lornan; Melanie J Percy; Amy V Jones; Nicholas C P Cross; Mary Frances Mc Mullin
Journal:  Haematologica       Date:  2005-12       Impact factor: 9.941

4.  Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia.

Authors:  N C Lea; Z Lim; N B Westwood; M J Arno; J Gäken; A Mohamedali; G J Mufti
Journal:  Leukemia       Date:  2006-05-04       Impact factor: 11.528

5.  Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)

Authors:  F Pane; F Frigeri; M Sindona; L Luciano; F Ferrara; R Cimino; G Meloni; G Saglio; F Salvatore; B Rotoli
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

6.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

7.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

8.  Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Qiaofang Chen; Pin Lu; Amy V Jones; Nicholas C P Cross; Richard T Silver; Y Lynn Wang
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

9.  Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation.

Authors:  Shinichi Kako; Yoshinobu Kanda; Tomohiko Sato; Susumu Goyama; Naohiro Noda; Eriko Shoda; Kumi Oshima; Morihiro Inoue; Koji Izutsu; Takuro Watanabe; Toru Motokura; Shigeru Chiba; Masashi Fukayama; Mineo Kurokawa
Journal:  Am J Hematol       Date:  2007-05       Impact factor: 10.047

10.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

View more
  4 in total

Review 1.  Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Authors:  Kim-Hien T Dao; Jeffrey W Tyner; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 2.  Chronic neutrophilic leukemia: new science and new diagnostic criteria.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-13       Impact factor: 11.037

Review 3.  Chronic neutrophilic leukemia complicated with monoclonal gammopathy of undetermined significance: A case report and literature review.

Authors:  Jia-Pei Gao; Li-Jia Zhai; Xiao-Hui Gao; Feng-Ling Min
Journal:  J Clin Lab Anal       Date:  2022-02-16       Impact factor: 2.352

Review 4.  Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia.

Authors:  Bing Li; Robert Peter Gale; Zhijian Xiao
Journal:  J Hematol Oncol       Date:  2014-12-12       Impact factor: 17.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.